Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
Quoin Pharmaceuticals (NASDAQ: QNRX) has appointed Sally Lawlor as its new Chief Financial Officer, effective immediately. Lawlor brings over 20 years of financial leadership experience, including her recent role at Sebela Pharmaceuticals and positions at Aptiv Plc and KPMG.
The appointment comes as Quoin advances its lead product QRX003 through pivotal clinical trials for Netherton Syndrome, with full enrollment expected in early to mid-Q1 2026. The company is preparing for a potential NDA filing next year and transition to a commercial-stage organization. Additionally, Quoin is developing treatments for Peeling Skin Syndrome and other rare dermatologic diseases through a novel topical rapamycin platform.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha nominato Sally Lawlor come nuovo Chief Financial Officer, con effetto immediato. Lawlor vanta oltre 20 anni di esperienza nella leadership finanziaria, con ruoli recenti presso Sebela Pharmaceuticals e precedenti incarichi in Aptiv Plc e KPMG.
La nomina avviene mentre Quoin porta avanti il suo prodotto di punta QRX003 in studi clinici pivotal per la Sindrome di Netherton, con arruolamento completo previsto tra l'inizio e la metà del primo trimestre 2026. L'azienda si sta preparando per una possibile presentazione della NDA il prossimo anno e per la transizione a una realtà commerciale. Inoltre, Quoin sta sviluppando trattamenti per la Peeling Skin Syndrome e altre malattie dermatologiche rare tramite una nuova piattaforma topica a base di rapamicina.
Quoin Pharmaceuticals (NASDAQ: QNRX) ha nombrado a Sally Lawlor como su nueva Chief Financial Officer, con efecto inmediato. Lawlor aporta más de 20 años de experiencia en liderazgo financiero, incluyendo su reciente puesto en Sebela Pharmaceuticals y cargos anteriores en Aptiv Plc y KPMG.
El nombramiento se produce mientras Quoin avanza su producto principal QRX003 en ensayos clínicos pivotal para el Síndrome de Netherton, con la inscripción completa prevista entre principios y mediados del primer trimestre de 2026. La compañía se está preparando para una posible presentación de la NDA el próximo año y para la transición a una organización en fase comercial. Además, Quoin desarrolla tratamientos para la Peeling Skin Syndrome y otras enfermedades dermatológicas raras mediante una novedosa plataforma tópica de rapamicina.
Quoin Pharmaceuticals (NASDAQ: QNRX)는 Sally Lawlor을 새로운 최고재무책임자(CFO)로 즉시 임명했습니다. Lawlor은 Sebela Pharmaceuticals에서의 최근 역할과 Aptiv Plc 및 KPMG에서의 경력을 포함해 20년 이상의 재무 리더십 경험을 보유하고 있습니다.
이번 임명은 Quoin이 주력 제품 QRX003를 Netherton 증후군에 대한 주요 임상시험 단계로 진행하는 가운데 이루어졌으며, 전원 등록은 2026년 1분기 초에서 중순 사이에 완료될 것으로 예상됩니다. 회사는 내년 잠재적인 NDA 제출과 상업 단계 조직으로의 전환을 준비하고 있습니다. 또한 Quoin은 새로운 국소용 라파마이신 플랫폼을 통해 Peeling Skin Syndrome 및 기타 희귀 피부 질환 치료제를 개발 중입니다.
Quoin Pharmaceuticals (NASDAQ: QNRX) a nommé Sally Lawlor comme nouvelle directrice financière (CFO), avec effet immédiat. Lawlor apporte plus de 20 ans d'expérience en direction financière, incluant son poste récent chez Sebela Pharmaceuticals ainsi que des fonctions chez Aptiv Plc et KPMG.
Cette nomination intervient alors que Quoin fait progresser son produit principal QRX003 dans des essais cliniques pivots pour le syndrome de Netherton, avec un recrutement complet prévu entre le début et le milieu du premier trimestre 2026. La société se prépare à un éventuel dépôt de NDA l'année prochaine et à la transition vers une organisation commerciale. De plus, Quoin développe des traitements pour la Peeling Skin Syndrome et d'autres maladies dermatologiques rares via une nouvelle plateforme topique à la rapamycine.
Quoin Pharmaceuticals (NASDAQ: QNRX) hat Sally Lawlor mit sofortiger Wirkung zur neuen Chief Financial Officer ernannt. Lawlor verfügt über mehr als 20 Jahre Erfahrung in leitenden Finanzfunktionen, zuletzt bei Sebela Pharmaceuticals sowie zuvor bei Aptiv Plc und KPMG.
Die Ernennung erfolgt, während Quoin sein Leitprodukt QRX003 in entscheidenden klinischen Studien für das Netherton-Syndrom vorantreibt; die vollständige Patientenrekrutierung wird für Anfang bis Mitte Q1 2026 erwartet. Das Unternehmen bereitet sich auf eine mögliche NDA-Einreichung im nächsten Jahr und den Übergang zu einer kommerziellen Organisation vor. Außerdem entwickelt Quoin über eine neuartige topische Rapamycin-Plattform Behandlungen für die Peeling Skin Syndrome und andere seltene dermatologische Erkrankungen.
- Strategic hiring of experienced CFO with commercial-stage finance expertise
- Lead product QRX003 advancing towards potential NDA filing in 2026
- Multiple clinical trials ongoing across U.S., Europe, and Middle East
- Diversified pipeline including treatments for multiple rare dermatologic diseases
- Current CFO Gordon Dunn departing the company
- No immediate revenue generation until potential product approval
ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization.
Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting firm.
In her most recent role at Sebela Pharmaceuticals, Ms. Lawlor managed financial reporting under U.S. GAAP and IFRS, oversaw global tax planning and compliance, as well as budgeting, forecasting, and external audits. Prior to Sebela, she served in senior tax leadership positions at Aptiv Plc and spent over a decade at KPMG advising multinational clients, primarily in the pharmaceutical and technology sectors. Ms. Lawlor is a Fellow of Chartered Accountants Ireland and a member of the Irish Taxation Institute.
“As we move closer to completing our QRX003 registrational trials in Netherton Syndrome and prepare for a potential NDA filing next year, we are aligning our leadership structure to support the next phase of Quoin’s growth,” said Dr. Michael Myers, Chief Executive Officer of Quoin. “We are thrilled to welcome Sally as Chief Financial Officer. She has extensive experience in commercial-stage finance, global tax strategy design and implementation, as well as multinational compliance, which we believe makes her exceptionally qualified to guide Quoin through our transition into a revenue-generating company. Sally adds invaluable expertise to our executive team at this pivotal time. I also want to thank Gordon Dunn for his dedicated contribution during his tenure as Quoin’s CFO. We wish him all the best in his future endeavors.”
Quoin is currently conducting two pivotal clinical studies for QRX003 in Netherton Syndrome across sites in the U.S., Europe and the Middle East, with full enrollment expected in early to mid-Q1 2026. The Company is also advancing development programs for Peeling Skin Syndrome and a novel topical rapamycin platform targeting a range of rare dermatologic diseases.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, angiofibromas and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to advancing QRX003 through pivotal clinical studies and preparing for potential commercialization, preparing for a potential NDA filing next year, aligning the Company’s leadership structure to support the next phase of Quoin’s growth, the expected contribution of Ms. Lawlor, transitioning Quoin into a revenue-generating company, attaining full enrollment in early to mid-Q1 2026 for two pivotal clinical studies for QRX003 in Netherton Syndrome across sites in the U.S., Europe and the Middle East, advancing development programs for Peeling Skin Syndrome and a novel topical rapamycin platform targeting a range of rare dermatologic diseases and Quoin’s products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, microcystic lymphatic malformations, venous malformations, angiofibromas and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company’s ability to pursue its regulatory strategy; the Company’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements; the Company’s ability to complete clinical trials on time and achieve desired results and benefits as expected; Ms. Lawlor’s ability to contribute to Quoin’s growth: the Company’s ability to transition into a revenue-generating company: and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Dr. Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
Who is the new CFO of Quoin Pharmaceuticals (NASDAQ: QNRX)?
When does Quoin Pharmaceuticals expect to complete enrollment for QRX003 trials?
What diseases is Quoin Pharmaceuticals (QNRX) targeting with its drug pipeline?
When does Quoin Pharmaceuticals plan to file its NDA for QRX003?
Where is Quoin Pharmaceuticals conducting clinical trials for QRX003?
